Discrete SARS-CoV-2 antibody titers track with functional humoral stability

离散的SARS-CoV-2抗体滴度与体液免疫功能稳定性相关

阅读:14
作者:Yannic C Bartsch # ,Stephanie Fischinger # ,Sameed M Siddiqui # ,Zhilin Chen ,Jingyou Yu ,Makda Gebre ,Caroline Atyeo ,Matthew J Gorman ,Alex Lee Zhu ,Jaewon Kang ,John S Burke ,Matthew Slein ,Matthew J Gluck ,Samuel Beger ,Yiyuan Hu ,Justin Rhee ,Eric Petersen ,Benjamin Mormann ,Michael de St Aubin ,Mohammad A Hasdianda ,Guruprasad Jambaulikar ,Edward W Boyer ,Pardis C Sabeti ,Dan H Barouch ,Boris D Julg ,Elon R Musk ,Anil S Menon ,Douglas A Lauffenburger ,Eric J Nilles ,Galit Alter

Abstract

Antibodies serve as biomarkers of infection, but if sustained can confer long-term immunity. Yet, for most clinically approved vaccines, binding antibody titers only serve as a surrogate of protection. Instead, the ability of vaccine induced antibodies to neutralize or mediate Fc-effector functions is mechanistically linked to protection. While evidence has begun to point to persisting antibody responses among SARS-CoV-2 infected individuals, cases of re-infection have begun to emerge, calling the protective nature of humoral immunity against this highly infectious pathogen into question. Using a community-based surveillance study, we aimed to define the relationship between titers and functional antibody activity to SARS-CoV-2 over time. Here we report significant heterogeneity, but limited decay, across antibody titers amongst 120 identified seroconverters, most of whom had asymptomatic infection. Notably, neutralization, Fc-function, and SARS-CoV-2 specific T cell responses were only observed in subjects that elicited RBD-specific antibody titers above a threshold. The findings point to a switch-like relationship between observed antibody titer and function, where a distinct threshold of activity-defined by the level of antibodies-is required to elicit vigorous humoral and cellular response. This response activity level may be essential for durable protection, potentially explaining why re-infections occur with SARS-CoV-2 and other common coronaviruses.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。